Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an intravenous formulation for intravenous use. It is used to prevent cerebral vasospasm following subarachnoid hemorrhage in patients at risk of delayed ischemic neurological deficits.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimotop acts on the cerebrovascular system to reduce the risk of vasospasm after hemorrhagic events. - Subarachnoid hemorrhage: helps prevent delayed cerebral vasospasm. - Cerebral vasospasm: reduces vessel narrowing after hemorrhage. - Neurological outcome after SAH: improves recovery by maintaining cerebral blood flow.

Adverse reactions may occur with nimodipine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient blood pressure drop. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with reddening of skin. - Dizziness: sensation of light‑headedness. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Hepatic enzyme elevation: monitor liver function tests. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: rare but potentially life‑threatening.

Before initiating Nimotop, consider the following safety measures. - Monitor blood pressure: watch for excessive hypotension. - Review concomitant antihypertensives: avoid additive blood pressure effects. - Assess hepatic function: dose adjustment may be needed in impairment. - Avoid strong CYP3A4 inhibitors: they can raise nimodipine levels. - Observe for allergic signs: discontinue if severe reaction occurs. - Store at room temperature: keep in the original pack, protect from moisture and light.

Nimodipine may interact with several drug classes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma concentrations. - Concomitant antihypertensives: cause additive hypotensive effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce therapeutic levels. - Other calcium channel blockers: may enhance hypotension. - NSAIDs: potential impact on renal function when combined. - Beta‑blockers: monitor for bradycardia.